Top Markets
Coin of the day
Addex Therapeutics Ltd Addex Therapeutics Ltd

Addex Therapeutics Ltd

ADXN
Clasificación en acciones #33378
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase,... Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Precio por acción
$0.05124204
Capitalización bursátil
$7.78M
Cambio (1 día)
0.51%
Cambio (1 año)
-23.73%
País
CH
Comercio Addex Therapeutics Ltd (ADXN)

Categoría

Ingresos de Addex Therapeutics Ltd (ADXN)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Addex Therapeutics Ltd, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Addex Therapeutics Ltd desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE